Pharmacovigilance (PV) represents a fundamental pillar of modern regulatory science, ensuring that medicinal products remain safe and effective throughout their lifecycle. The World Health Organization (WHO) defines PV as ?the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine or vaccine-related problem? [1]. The overarching objective of pharmacovigilance istomaintain a favorable benefit risk balance by continuously monitoring the safety profile of medicinal products after approval. Its core goals include improving patient care, detecting previously unknown or changing adverse drug reactions (ADRs), identifying risk factors, quantifying benefit risk relationships, and promoting rational and safe use of medicines [2] . Clinical trials conducted before drug approval are limited by controlled environments, restricted inclusion criteria, short durations, and relatively small sample sizes [3]. Consequently, rare, delayed, or population-specific ADRs often emerge only after a product enters the market. Post-marketing surveillance (PMS) bridges this gap by extending drug evaluation into real world conditions, encompassing diverse populations, comorbidities, and long-term usage [4]. PMS activities such as spontaneous reporting, active surveillance, cohort event monitoring, and patient registries enable regulators and manufacturers to detect new signals, re-evaluate benefit risk profiles, and implement timely safety interventions [5].
Figure 1: Historical Evolution of Pharmacovigilance
The discipline of pharmacovigilance evolved through a series of landmark drug safety crises. The 1937 Sulfanilamide disaster in the United States, caused by diethylene glycol toxicity,led to the enactment of the U.S. Food, Drug, and Cosmetic Act of 1938 requiring proof of safety prior to marketing [6]. The Thalidomide tragedy of the late 1950s and early 1960s, resulting in thousands of congenital malformations, catalyzed global awareness of the need for systematic post-approval safety monitoring [7]. In response, the WHO established the Programme for International Drug Monitoring in 1968, which evolved into the Uppsala MonitoringCentre(UMC) aglobal hub forADR datacollection and signal detection [8]. Since then, pharmacovigilance has expanded into a globally coordinated system supported by regulatory authorities, healthcare professionals, and the pharmaceutical industry. Regulatory oversight after drug approval is crucial for maintaining the integrity of the healthcare system. Agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency(EMA), and India’sCentralDrugsStandardControlOrganization(CDSCO)mandate robust post-marketing surveillance through mechanisms like Periodic Safety Update Reports (PSURs), Periodic Benefit Risk Evaluation Reports (PBRERs), and Risk Management Plans (RMPs) [9,10]. Regulatory actions based on PV data such as safety labeling changes,restrictions of use, or product withdrawal illustrate the dynamic nature of benefit–risk assessment [11]. Effective pharmacovigilance systems depend on transparent communication, inter-agency cooperation, and the integration of digital tools to manage large-scale safetydata. ADRs remain a major cause of morbidity and mortality worldwide. Studies estimatethatADRsaccountfor3-10%ofallhospitaladmissions,with5-15% of hospitalized patients experiencing at least one ADR duringtheir stay [12]. In Europe alone, ADRs contribute to over 197,000 deaths annually and incur healthcare costs exceeding €79 billion [13].
2.0 REGULATORY FRAME WORK FOR PHARMACOVIGILANCE
2.1 Global Regulatory Landscape
Pharmacovigilance (PV) is globally coordinated through international frameworksestablished to standardize safety monitoring, harmonize data collection, and facilitate communication between national authorities. The World Health Organization (WHO) plays a central coordinating role through the Programme for International Drug Monitoring (PIDM), established in 1968 following the thalidomide tragedy. The programme is managed by the UppsalaMonitoringCentre(UMC)inSweden,whichmaintainstheglobal VigiBasedatabase the world’s largest repository of individual case safety reports (ICSRs), contributed by more than 170 member states [14,15]. WHO-UMC supports member countries in signal detection, causality assessment, and training for national PV centers(16). The global collaboration allows early identification of safety concerns that might not be apparent within a single region. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has played a pivotal role in unifying global PV standards amongregulatory agencies and the pharmaceutical industry. Two landmark guidelines are particularly relevant:
• ICH E2E: Pharmacovigilance Planning (2004)provides a structured approach for planning PV activities during drug development and after approval. It requires manufacturers to develop Risk Management Plans (RMPs) that proactively identify potential risks, proposemitigation measures, and specifypost-marketingstudies when necessary(17).
• ICH E2D: Post-Approval Safety Data Management (2003)establishes harmonized standards for handling safety data after marketing, including the format and timelines for periodic reporting and expedited case reporting to regulators [18].
Figure 2: Global Regulatory Frame work of Pharmacovigilance.
2.2 Regional RegulatorySystems
United States (FDA)-The U.S. Food and Drug Administration (FDA) operates one of the most mature pharmacovigilance infrastructures globally. Its MedWatch program (established 1993) enables healthcare professionals and consumers to voluntarily report adverse eventsand product problems [19]. Additionally, the Sentinel Initiative launched in 2008 useselectronic health data from over 100 million individuals to actively monitor medical product safety, representing a major shift toward proactive, data-driven surveillance [20]. The FDA requires Periodic Benefit-Risk Evaluation Reports (PBRERs) and enforces Risk Evaluation and Mitigation Strategies (REMS) when necessary to ensure safe use of high-riskproducts [21].
European Union (EMA)-The European Medicines Agency (EMA) coordinates PV within the EU through the EudraVigilance database, operational since 2001, which serves as a centralized system for reporting and evaluating suspected ADRs [22]. The Good Pharmacovigilance Practice (GVP) modules, implemented under Regulation (EU) No. 1235/2010, outline mandatory requirements for safety reporting, signal management, and RMPimplementation [23].TheEUalsoemphasizestransparencyperiodicsafetysummaries
and public safety communications are published in the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) database [24].
India (PvPI and CDSCO)-India established the Pharmacovigilance Programme of India (PvPI) in 2010 under the Central Drugs Standard Control Organization (CDSCO) to strengthen post-marketing drug safety. The Indian Pharmacopoeia Commission (IPC) functions as the National Coordination Centre (NCC-PvPI), overseeing ADR reporting through more than 600 Adverse Drug Reaction Monitoring Centres (AMCs) across the country [25]. The CDSCO mandates the submission of Periodic Safety Update Reports (PSURs) everysix months for the first two years after approval and annuallyfor the next two years [26]. PvPI’s integration with WHO-UMC enhances India’s contribution to global drug- safety data.
Japan, Canada, and Australia- Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)enforcesstringentpost-marketingsurveillanceobligations,includingre-examination periods and re-evaluation systems that require periodic reassessment of product safety [27]. Health Canada operates the Canada Vigilance Program, facilitating ADR reporting through regional centers and maintaining an open access database [28]. The Therapeutic Goods Administration (TGA) in Australia similarly mandates PV plans, periodic reporting, andrapid alert dissemination through the Database of Adverse Event Notifications (DAEN) [29].
2.3 Industry Responsibilities
Pharmaceutical companies, as Marketing Authorization Holders (MAHs), bear direct legal and ethical responsibilities for pharmacovigilance. Key obligations include:
• Establishment of a robust PV system with qualified personnel (Qualified Person for Pharmacovigilance -QPPV).
• Expedited reporting of serious and unexpected ADRs within specified timelines (15 days for fatal or life-threatening cases).
• Preparation and submission of PSURs and PBRERs, summarizing global safety data, cumulative analyses, and benefit risk evaluations [30].
• Development and implementation of Risk Management Plans (RMPs) describing identified and potential risks, safety specifications, and pharmacovigilance activitiesto minimize harm [31].
• Continuoussignaldetectionusingstatisticalalgorithmsandreal-worlddatatoidentify new safety concerns and communicate them promptly to regulators.
Failure to comply with PV obligations can result in regulatory sanctions, market withdrawal, or criminal penalties, depending on jurisdiction [32]. Effective industry PV practice requires integrating scientific expertise, data analytics, and regulatory intelligence to ensure that patient safety remains paramount throughout a product’s lifecycle.
Figure 3: Responsibilities of Marketing Authorization Holders
3.0 POST-MARKETING SURVEILLANCE MECHANISMS
Post-marketing surveillance (PMS) mechanisms encompass a diverse range of tools and methodologies designed to continuously monitor the safety and effectiveness of medicinal productsoncetheyareintroducedintothemarket.ThecornerstoneofPMSisthespontaneous reporting system (SRS), wherein healthcare professionals and consumers voluntarily submit individual case safety reports (ICSRs) of suspected adverse drug reactions (ADRs) to national pharmacovigilance centers or regulatory databases such as EudraVigilance, FAERS (FDA Adverse Event Reporting System), and VigiBase maintained by the WHO-Uppsala Monitoring Centre [33]. Complementing this passive approach, active surveillance systems including the U.S. Sentinel Initiative and the Vaccine Adverse Event Reporting System (VAERS) proactively collect and analyze electronic health data from large populations to identifyand quantifydrug-related risks in near real time [34]. Prescription Event Monitoring (PEM) serves as another important PMS tool, tracking adverse events among cohorts of patients receiving newly marketed drugs through prescription databases, thus capturing real-world utilization and safety patterns [35]. Additionally, patient registries and electronic health records (EHRs) provide longitudinal data on drug exposure, outcomes, and comorbidities, enabling the assessment of long-term safety and comparative effectiveness across diverse populations [36]. The integration of patient-reported outcomes (PROs) and digital health technologies such as mobile applications, wearable sensors, and onlinereporting portals has further revolutionized PMS by facilitating real-time, patient-centered monitoring of ADRs and treatment adherence [37].
Figure 4: Overview of Post-Marketing Surveillance Mechanisms
4.0 SIGNAL DETECTION AND RISK ASSESSMENT
Signal detection and risk assessment form the cornerstone of pharmacovigilance, serving as critical processes for identifying, validating, and quantifying potential safety concerns related to medicinal products after marketing authorization. In pharmacovigilance, a ?signal? is defined as information arising from one or multiple sources (including spontaneous reports, studies, or scientific literature) that suggests a new potential causal association or a new aspect of a known association between a drug and an adverse event, which warrants further investigation [38].Theprocessbegins withdataminingandstatisticalmethodsappliedtolarge pharmacovigilance databases such as the WHO’s VigiBase, FDA’s FAERS, or EMA’s EudraVigilance. Among these, disproportionality analysis methods such as the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Information Component (IC), and Empirical Bayes Geometric Mean (EBGM) are widely used to detect signals by identifying drug-event pairs reported more frequently than expected [39]. Once potential signals are identified,caseevaluationandcausalityassessmentareconductedtodeterminethelikelihood ofa true causal relationship between the drug and theadverse event. The WHO-UMC system and the Naranjo algorithm are the most commonly used standardized tools for such assessments. The WHO-UMC system classifies causality as certain, probable, possible, unlikely, conditional/unclassified, or unassessable, based on clinical, temporal, and pharmacological evidence [40]. The Naranjo scale, on the other hand, utilizes a structured questionnaire that assigns numerical scores to determine the probability of an adverse event being drug-related, facilitating reproducibility and transparency in decision-making [41]. Following causality assessment, benefit–risk evaluation becomes central to regulatory and clinical decisions. This process integrates quantitative and qualitative evidence on the drug’s therapeutic benefits versus potential risks, guided byframeworks developed byagencies such as the EMA and FDA. The benefit risk profile may evolve throughout a product’s lifecycle, necessitating continuous reassessment based on new safety data, real world evidence, and patient-reported outcomes [42]. If the risk is confirmed and outweighs the benefit, regulators and Marketing Authorization Holders (MAHs) may implement risk minimization actions, such as label modifications, risk management plans (RMPs), restricted use, or even market withdrawal [43].
5.0 EMERGING TRENDS AND TECHNOLOGICAL INNOVATIONS
The landscape of pharmacovigilance (PV) is rapidly evolving with the integration of digital technologies, artificial intelligence (AI), big data analytics, and genomics, fundamentally transforming how adverse drug reactions (ADRs) are detected, assessed, and managed in real time. Artificial Intelligence (AI) and Machine Learning (ML) are at the forefront of this transformation, enabling automated case processing, natural language processing (NLP)- based literature screening, and predictive modeling for early signal detection from massive datasetssuch asspontaneousreportingsystems(e.g., FAERS,EudraVigilance) andelectronic health records (EHRs) [44]. ML algorithms such as disproportionality analysis, Bayesian networks, and deep learning models can identify subtle safety signals that traditional statistical methods might overlook, improving both sensitivity and specificity in ADR detection [45]. The use of Big Data and Real-World Evidence (RWE) sourced from clinical registries,hospitalrecords,insuranceclaims,andpatient-generateddatahasbeenendorsedby global regulatory bodies, including the U.S. FDA’s Sentinel Initiative and the European MedicinesAgency’sDARWINEUnetwork,tostrengthen post-marketsafetysurveillance [46]. These data ecosystems provide continuous, population level insights into drug performance, enabling timely regulatory interventions and benefit risk reassessment across diverse demographics. Another pivotal advancement is the integration of pharmacogenomics into pharmacovigilance, which links individual genetic variability to drug efficacy and ADR susceptibility. Understanding pharmacogenetic profiles helps identify high risk populations for specific toxicities, as seen with HLA-B57:01 and abacavir hypersensitivity, or CYP2C9/VKORC1 variants and warfarin bleeding risk [47]. Incorporating pharmacogenomic markers into PV databases facilitates the prediction of ADRs before clinical manifestationand supports the evolution of precision pharmacovigilance [48]. Simultaneously, digital health tools including mobile health (mHealth) applications, wearable sensors, and Internet of Medical Things (IoMT) devices enable patient centered, real-time ADR monitoring. Patients can directly report adverse effects, track medication adherence, and share biometric data(e.g., heart rate, blood glucose, sleep patterns), contributing to continuous safety signal generation outside traditional clinical settings [49]. Integration of wearable-derived data with EHRs enhances long-term safety tracking and personalized risk assessment, while telemedicine platforms are further expanding the scope of remote pharmacovigilance [50].
Furthermore, automation in PV workflows through robotic process automation (RPA), AI- assistedcasetriage, andintelligentdata extraction significantlyreducesmanualworkloadand reporting delays while improving data consistency and regulatory compliance [51]. NLP-based algorithms now process thousands of individual case safety reports (ICSRs) daily, automatically detecting duplicates, coding MedDRA terms, and identifying potential safety signals [52]. Advanced signal detection and visualization tools, such as Bayesian confidence propagation neural networks (BCPNN) and AI-driven dashboards, provide regulators and industrywith real-timedecision support forbenefit–risk evaluation. Blockchain technologyis also being explored for secure, traceable, and transparent exchange of PV data among stakeholders while maintaining patient privacy and data integrity[53]. The convergence of AI, RWE,pharmacogenomics,anddigitalhealthtechnologiesisusheringinaneweraofPredictive Pharmacovigilance?, characterized by proactive risk identification, continuous monitoring, and patient engagement. Regulatoryagencies are respondingbyissuing guidance on the validation and ethical use of AI/ML in PV and encouraging the integration of these tools into post-marketing surveillance frameworks [54].
Figure 5: Technological Advancements in Pharmacovigilance.
6.0 CURRENT CHALLENGES IN PHARMACOVIGILANCE
Current challenges in pharmacovigilance (PV) encompass a wide range of scientific, operational, and ethical issues that hinder the global optimization of post-marketing drug safetysystems. Oneofthemostpersistentbarriers isunderreportingof adversedrugreactions (ADRs), with studies indicating that fewer than 10% of all ADRs are formally reported, largelydue to limited awareness, time constraints, and uncertainty regarding causality among healthcare professionals and patients[55]. Even when reported, data quality issues such as incomplete clinical details, duplicate entries, and inconsistent coding reduce the reliability of signal detection and complicate causality assessment. Another major limitation lies in global harmonization and data sharing, as disparate national regulations, incompatible reporting formats, and restricted cross-border access to safetydatabases (e.g., FAERS, EudraVigilance, VigiBase) impede timely identification of global safety signals[56]. The management of biologicals, biosimilars, and gene therapies introduces additional complexity, given their molecular diversity, immunogenicity risks, and variability in manufacturing processes; these therapies often require long-term follow-up studies and specialized registries for adequate monitoring[57]. The COVID-19 pandemic underscored both the strengths and weaknesses of PV systems, highlighting the need for real-time vaccine safety surveillance and transparent public communication to address misinformation and vaccine hesitancy [58]. Furthermore, the increasing use of digital PV systems and AI driven surveillance tools has raised significant ethical and privacy concerns, especially regarding data ownership, informed consent, and compliance with regulations such as the General Data Protection Regulation (GDPR) [59]. In addition, low and middle income countries (LMICs) face substantial capacity building challenges, including limited infrastructure, insufficientlytrained PV professionals, and weak regulatory frameworks, which collectively constrain effective ADR monitoring and global data contribution [60]. Addressing these challenges requires harmonized regulatory standards, international collaboration, integration of advanced technologies with ethical oversight, and investment in global training and resource development to create equitable, transparent, and efficient pharmacovigilance systems capable of protecting public health worldwide [61].
Figure 6: Global Challenges in Pharmacovigilance
7.0 REGULATORY RESPONSIBILITIES AND INDUSTRY COLLABORATION
Regulatory responsibilities and industry collaboration in pharmacovigilance (PV) represent a coordinated global framework to ensure the ongoing monitoring of medicinal product safety throughout the post marketing phase. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) in India are responsible for establishing PV legislation, developing international guidelines (e.g., ICH E2E Pharmacovigilance Planning, EMA Good Pharmacovigilance Practice Modules), and ensuring compliance through regular inspections andauditsofMarketingAuthorizationHolders(MAHs) [62,63].MAHsbearthelegalobligation to collect, analyze, and report adverse drug reactions (ADRs), maintain comprehensive Risk Management Plans (RMPs), submit Periodic Safety Update Reports (PSURs) or Periodic BenefitRiskEvaluationReports(PBRERs),andimplementpostauthorizationsafetystudieswhere required [64]. Healthcare professionals act as primary sources of ADR data by identifying and reporting suspected adverse events, while patients and consumersincreasingly contribute through online and mobile reporting platforms, strengthening real- world safety data collection [65]. Regulatory inspections and internal or third-party auditsverify adherence to Good Pharmacovigilance Practices (GVP), ensuring data quality, timely reporting, and the effectiveness of risk-minimization measures [66]. Transparency and public communication are critical for maintaining public trust regulators and MAHs disseminate emerging safety signals, label updates, and benefit risk evaluations via official bulletins, databases, and media platforms [67]. Pharmacovigilance Agreements (PVAs) between MAHs, local affiliates, contract research organizations (CROs), and service providers define mutual responsibilities, data-sharing timelines, and escalation procedures, ensuring globalcompliance and consistency in safety reporting [68]. At the international level, organizations such as the World Health Organization’s Uppsala Monitoring Centre (WHO-UMC), the Council for International Organizations of Medical Sciences (CIOMS), and the International Council for Harmonisation (ICH) promote cross-border data sharing, harmonized reporting standards, and collaborative signal detection initiatives. Together, these sharedresponsibilities and partnerships among regulators, industry, healthcare professionals, and patients underpin a proactive global PV network enhancing patient safety, fostering accountability, and strengthening public confidence in drug regulation systems.[69]
8.0 ETHICAL AND LEGAL CONSIDERATIONS
Ethical and legal considerations in pharmacovigilance (PV) and post-marketing surveillance (PMS) are critical for ensuring patient safety, data integrity, and regulatory compliance. Protection of patient privacy during adverse drug reaction (ADR) reporting requires strict adherence to international data protection laws such as the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, both mandating anonymisation and secure handling of personal health information [70]. Informed consent and transparency in PMS studies are equally vital, as participants must be made aware of study objectives, data usage, potential risks, and benefits, in accordance with Good Pharmacovigilance Practices (GVP) and World Health Organization (WHO) ethical guidelines [71]. Non compliance with these ethical or legal obligations such as failure to report ADRs or maintain robust pharmacovigilancesystemscanresultinsevereregulatoryconsequences,includingfinancial
penalties, suspension of marketing authorisation, or product withdrawal by agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Therefore, the integration of ethical oversight, informed consent procedures, and legal accountabilityinto pharmacovigilancesystems is fundamental to maintainingpublictrust and protecting patient welfare [72].
9.0 CASE STUDIES
1. Thalidomide Tragedy and Its Regulatory Aftermath
The thalidomide tragedy of the late 1950s and early 1960s, in which the drug caused severe congenital malformations including phocomelia in more than 10,000 infants worldwide, remains one of the most consequential events in drug safety history. Its widespread use in pregnant women without reproductive toxicity testing exposed major weaknesses in regulatory oversight at the time. The aftermath led to global reforms such as the Kefauver Harris Drug Amendments (USA), the development of structured adverse drug reaction(ADR) reporting systems, and the establishment of the WHO Programme for International Drug Monitoring (UMC) [73]. These regulatory changes laid the foundation for modern pharmacovigilance systems and mandatory pre-clinical teratogenicity testing.
2. Vioxx (Rofecoxib) Withdrawal and Lessons Learned
Vioxx (rofecoxib), approved in 1999 as a selective COX-2 inhibitor for pain and arthritis,was withdrawn globally in 2004 after evidence showed an increased risk of myocardial infarction and stroke. Despite emerging early safety signals, inconsistent reporting and delayed risk communication resulted in prolonged patient exposure. The withdrawal highlighted the importance of active surveillance, transparency in safety data, and robustpost-marketingriskmanagementplans. It also prompted regulatory agencies such as the FDA andEMAtostrengthenriskevaluationstrategiesandenhancereal-timesignaldetectionusing pharmaco epidemiological methods [74,75].
3. COVID-19 Vaccine Safety Surveillance Frameworks
During the COVID-19 pandemic, global regulatory bodies implemented enhanced and real- time vaccine pharmacovigilance frameworks. Systems like the U.S. Vaccine Adverse Event Reporting System (VAERS), V-safe, Eudra Vigilance in Europe, and India’s AEFI surveillancenetworkenabledrapiddetectionofrareadverseeventssuchasmyocarditisfollowing mRNA vaccines and thrombosis with thrombocytopenia syndrome (TTS) after adenoviral vector vaccines. The WHO’s Global Advisory Committee on Vaccine Safety (GACVS) also coordinated international risk assessment, allowing transparent communication and rapid public health responses. These experiences demonstrated the importance of digital tools, active surveillance, and global data sharing during mass immunization programs [76,77].
4. India’s Recent Pharmacovigilance Success Storiesand Gaps
India's Pharmacovigilance Programme of India (PvPI) has significantly improved national ADR reporting since 2010, contributing large numbers of reports to WHO’sVigiBase and expanding more than 600 ADR Monitoring Centres across the country. Successes include the Haemovigilance and Materiovigilance Programs and strong COVID-19 vaccine safety oversight. However, underreporting, limited participation of private hospitals, insufficient training, and low patient awareness remain major challenges. Strengthening active surveillance, integrating digital health-record systems, and enhancing community-level reporting are critical to improving national pharmacovigilance capacity[78].
10. FUTURE DIRECTIONS
Pharmacovigilance and post-marketing surveillance remain indispensable to ensuring the safety and effectiveness of medicinal products after their approval and widespread use. As drug development expands and real-world therapeutic landscapes become increasingly complex, the need for robust, harmonized, and technology enabled PV systems is more critical than ever. Historical and contemporary drug safety events underscore the importance of continuous monitoring, transparent communication, and evidence based regulatory action. The integration of advanced tools such as artificial intelligence, real world evidence, pharmacogenomics, and digital health technologies has begun to shift pharmacovigilance from a reactive paradigm to a predictive and proactive model capable of earlier signal detection and targeted risk mitigation. However, persistent challenges including underreporting, heterogeneous global regulatory frameworks, ethical considerations, and limited PV capacity in developing regions continue to constrain system efficiency.Addressing these gaps will require sustained international collaboration, stronger patient engagement, regulatory innovation, and investment in training and digital infrastructure. Looking forward, future pharmacovigilance must prioritize global harmonization, patient- centered approaches, data-driven risk prediction, and transparent regulatory processes to safeguard public health and ensure that therapeutic advances deliver maximal clinical benefit with minimal harm.
[1] Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259. https://doi.org/10.1016/s0140-6736(00)02799-9
[2] Meyboom, R. H., Egberts, A. C., Edwards, I. R., Hekster, Y. A., De Koning, F. H., &Gribnau, F. W. (1997). Principles of signal detection in pharmacovigilance. Drug Safety, 16(6), 355–365. https://doi.org/10.2165/00002018-199716060-00002
[3] Ioannidis, J. P. A. (2006). Evolution and Translation of Research Findings: From Bench to Where. PLoS Clinical Trials, 1(7), e36. https://doi.org/10.1371/journal.pctr.0010036
[4] Platt, R., Wilson, M., Chan, K. A., Benner, J. S., Marchibroda, J., & McClellan, M. (2009). The New Sentinel Network — Improving the Evidence of Medical-Product Safety. New England Journal of Medicine, 361(7), 645–647. https://doi.org/10.1056/nejmp0905338
[5] Hazell, L., &Shakir, S. a. W. (2006). Under-Reporting of adverse drug reactions. Drug Safety, 29(5), 385–396. https://doi.org/10.2165/00002018-200629050-00003
[6] Wax, P. M. (1995). Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Annals of Internal Medicine, 122(6), 456–461. https://doi.org/10.7326/0003-4819-122-6-199503150-00009
[7] Vargesson, N. (2015). Thalidomide?induced teratogenesis: History and mechanisms.Birth Defects Research Part C Embryo Today Reviews, 105(2), 140–156. https://doi.org/10.1002/bdrc.21096
[8] Lindquist, M. (2008). VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal, 42(5), 409–419. https://doi.org/10.1177/009286150804200501
[9] Food and Drug Administration (FDA). Guidance for industry: postmarketing safety reporting. FDA; 2015.
[10] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). EMA; 2017.
[11] Miguel, A., Azevedo, L. F., Araújo, M., & Pereira, A. C. (2012). Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta?analysis. Pharmacoepidemiology and Drug Safety, 21(11), 1139–1154. https://doi.org/10.1002/pds.3309
[12] Aizpurua?Arruti, X., Goyenechea, E., Isla, A., Oñatibia?Astibia, A., Malet?Larrea, A., Gastelurrutia,M.Á.,Solinís,M.Á.,&DelPozo?Rodriguez,A.(2025).
[13] Additional monitoring on pharmacovigilance and pharmacists’ role: A scoping review. Pharmacoepidemiology and Drug Safety, 34(9), e70201.https://doi.org/10.1002/pds.70201
[14] World Health Organization. WHO Programme for International Drug Monitoring (PIDM). WHO; 2023.
[15] Lindquist, M. (2008b). VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal, 42(5), 409–419. https://doi.org/10.1177/009286150804200501
[16] Hancock-Howard,R.L.(2010).DeborahMarshall,PhD.Patient,3(4),207–208. https://doi.org/10.2165/11531080-000000000-00000
[17] InternationalCouncilforHarmonisation.ICHE2EPharmacovigilancePlanning.ICH; 2004.
[18] InternationalCouncil forHarmonisation. ICHE2DPost-Approval SafetyData Management. ICH; 2003.
[19] U.S.FoodandDrugAdministration.MedWatch:TheFDASafetyInformationandAdverse Event Reporting Program. FDA; 2023.
[20] Desai,R.J.,Matheny,M.E.,Johnson,K.,Marsolo,K.,Curtis,L.H.,Nelson,J.C., Heagerty, P. J., Maro, J., Brown, J., Toh, S., Nguyen, M., Ball, R., Pan, G. D., Wang, S. V., Gagne, J. J., &Schneeweiss, S. (2021b). Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework.Npj Digital Medicine, 4(1), 170.https://doi.org/10.1038/s41746-021-00542-0
[21] Pharmacovigilance Programme of India (PvPI). Indian Pharmacopoeia Commission; 2023.
[22] Central Drugs Standard Control Organization (CDSCO). Schedule Y – Drugs & Cosmetics Rules: Guidelines for Pharmacovigilance. CDSCO; 2020.
[23] Pharmaceuticals and Medical Devices Agency(PMDA). Post-marketing safetymeasures and re-examination periods in Japan. PMDA; 2022.
[24] International Council for Harmonisation. ICH E2C(R2)Periodic Benefit–Risk Evaluation Report. ICH; 2012.
[25] Bahri, P., Tsintis, P., & Waller, P. C. (2006). Regulatory pharmacovigilance in the EU. ResearchGate, 185–198. https://doi.org/10.1002/9780470059210.ch14
[26] De Las Cuevas, C., Sanz, E. J., & De Leon, J. (2024). Pharmacovigilance in action: Utilizing VigiBase data to improve Clozapine safety. Patient Preference and Adherence, Volume 18, 2261–2280. https://doi.org/10.2147/ppa.s495254
[27] Ball, R., Robb, M., Anderson, S., & Pan, G. D. (2015). The FDA’s sentinel initiative—A comprehensive approach to medical product surveillance. Clinical Pharmacology & Therapeutics, 99(3), 265–268. https://doi.org/10.1002/cpt.320
[28] Huang, Y., Moon, J., & Segal, J. B. (2014). A comparison of active adverse event surveillance systems worldwide. Drug Safety, 37(8), 581–596. https://doi.org/10.1007/s40264-014-0194-3
[29] McGettigan, P., Olmo, C. A., Plueschke, K., Castillon, M., Zondag, D. N., Bahri, P.,Kurz, X., &Mol, P. G. M. (2019). Patient Registries: an underused resource formedicines evaluation. Drug Safety, 42(11), 1343–1351. https://doi.org/10.1007/s40264-019-00848-9
[30] Santonen, T., Petsani, D., Julin, M., Garschall, M., Kropf, J., Van Der Auwera, V., Bernaerts, S., Losada, R., Almeida, R., Garatea, J., Muñoz, I., Nagy, E., Kehayia, E., De Guise, E., Nadeau, S., Azevedo, N., Segkouli, S., Lazarou, I., Petronikolou, V., . . . Konstantinidis, E. (2021). Cocreating a Harmonized living lab for Big Data–Driven Hybrid persona Development: protocol for cocreating, testing, and seeking consensus. JMIR Research Protocols, 11(1), e34567. https://doi.org/10.2196/34567
[31] Karimi, G., Star, K., Norén, G. N., &Hägg, S. (2013). The impact of duration of treatment on Reported Time-to-OnSeT in Spontaneous Reporting Systems for pharmacovigilance. PLoS ONE, 8(7), e68938. https://doi.org/10.1371/journal.pone.0068938
[32] Dhodapkar, M. M., Shi, X.,Ramachandran, R., Chen, E.M., Wallach, J. D., &Ross, J. S. (2022). Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. BMJ, 379, e071752. https://doi.org/10.1136/bmj-2022-071752
[33] Fusaroli, M., Salvo, F., Begaud, B., AlShammari, T. M., Bate, A., Battini, V., Brueckner, A., Candore, G., Carnovale, C., Crisafulli, S., Cutroneo, P. M., Dolladille, C., Drici, M., Faillie, J., Goldman, A., Hauben, M., Herdeiro, M. T., Mahaux, O., Manlik, K., . . . Khouri, C. (2024). The REporting of a Disproportionality Analysis for DRUG Safety Signal Detection using Individual Case SafetyReports in PharmacoVigilance (READUS- PV): Explanation and Elaboration. Drug Safety, 47(6), 585–599. https://doi.org/10.1007/s40264-024-01423-7
[34] Jiao, X., Pu, L., Lan, S., Li, H., Zeng, L., Wang, H., & Zhang, L. (2024). Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic review. Pharmacoepidemiology and Drug Safety, 33(3), e5768. https://doi.org/10.1002/pds.5768
[35] Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239–245. https://doi.org/10.1038/clpt.1981.154
[36] Juhaeri, J. (2019). Benefit–risk evaluation: the past, present and future. TherapeuticAdvances in Drug Safety, 10, 2042098619871180. https://doi.org/10.1177/2042098619871180
[37] Sullivan, T., Zorenyi, G., Feron, J., Smith, M., & Nord, M. (2023). A Structured Benefit- Risk Assessment operating model for investigational medicinal products in the pharmaceutical industry. Therapeutic Innovation & Regulatory Science, 57(4), 849–864. https://doi.org/10.1007/s43441-023-00508-2
[38] Li, Y., Tao, W., Li, Z., Sun, Z., Li, F., Fenton, S., Xu, H., & Tao, C. (2024). Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. Journal of Biomedical Informatics, 152, 104621. https://doi.org/10.1016/j.jbi.2024.104621
[39] Khemani, B., Malave, S., Shinde, S., Shukla, M., Shikalgar, R., &Talwar, H. (2025). AI- driven pharmacovigilance: Enhancing adverse drug reaction detection with deep learning and NLP. MethodsX, 15, 103460. https://doi.org/10.1016/j.mex.2025.103460
[40] JoseR.Machinelearningindrugsafety:exploringapplicationsandaddressingchallenges for improved patient safety. J Pharmacovigilance Drug Res. 2024; (5):139.
[41] Patadia, V., Manlik, K., Gipson, G., Willis, J. C., Namuyinga, R., McDermott, R., Shaw, A., Miller, M. K., Asubonteng, J., Golchin, N., & Von Klot, S. (2024). Leveraging Real- World data in safety signal assessment. Therapeutic Innovation & Regulatory Science, 58(6), 1062–1070. https://doi.org/10.1007/s43441-024-00682-x
[42] Sunwoo, Y., Eom, S. H., Yun, J. S., Kim, Y., Lee, J., Lee, S. H., Shin, S., & Choi, Y. J. (2024). Real-World Data-Derived Pharmacovigilance on Drug-Induced cognitive impairment utilizing a nationwide spontaneous adverse reporting system. Medicina,60(7), 1028. https://doi.org/10.3390/medicina60071028
[43] Cacabelos, R., Cacabelos, N., &Carril, J. C. (2019). The role of pharmacogenomics in adverse drug reactions. Expert Review of Clinical Pharmacology, 12(5), 407–442. https://doi.org/10.1080/17512433.2019.1597706 Liou, S.,Stringer, F., & Hirayama,M. (2012). Theimpact ofpharmacogenomics research on drug development. Drug Metabolism and Pharmacokinetics, 27(1), 2–8. https://doi.org/10.2133/dmpk.dmpk-11-rv-093
[44] Praveen, J. (2023). Catalyzing Drug Safety: Harnessing IoT and Block chain Technology and its Synergy in Pharmacovigilance. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 13–17. https://doi.org/10.37022/jiaps.v8i3.478
[45] Nagar, A., Gobburu, J., &Chakravarty, A. (2025). Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration. Therapeutic Advances in Drug Safety, 16, 20420986251361435. https://doi.org/10.1177/20420986251361435
[46] Avunoori, P., Aishwarya, N., Nandhini, K., Prasanna, L., &Mounika, G. (2025). A review on block chain technology in healthcare: Assessing its impact on pharmacovigilance and drug tracking. Journal of Advances in Medicine and Medical Research, 37(4), 301–308. https://doi.org/10.9734/jammr/2025/v37i45804
[47] García-Abeijon, P., Costa, C., Taracido, M., Herdeiro, M. T., Torre, C., &Figueiras, A. (2023). Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update. Drug Safety, 46(7), 625–636. https://doi.org/10.1007/s40264-023-01302-7
[48] Belton, K., Lewis, S., Payne, S., Rawlins, M., & Wood, S. (1995). Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom [see comments]. British Journal of Clinical Pharmacology, 39(3), 223–226. https://doi.org/10.1111/j.1365-2125.1995.tb04440.x
[49] Gadhade, J. S., &Hiray, R. S. (2021). Global Pharmacovigilance, challenges, and future considerations: West globe and East globe. Journal of Pharmacovigilance and Drug Research, 2(2), 3–6. https://doi.org/10.53411/jpadr.2021.2.2.2
[50] Petitpain, N., Antoine, M. L., Beurrier, M., Micallef, J., &Fresse, A. (2023). Pharmacovigilance of gene therapy medicinal products. Rare Disease and Orphan Drugs Journal, 2(4). https://doi.org/10.20517/rdodj.2023.19
[51] Chandler, R. E., McCarthy, D., Delumeau, J., & Harrison-Woolrych, M. (2020). The role of pharmacovigilance and ISOP during the global COVID-19 pandemic. Drug Safety, 43(6), 511–512. https://doi.org/10.1007/s40264-020-00941-4
[52] Lino, M. M., Mather, S., Trani, M., Chen, Y., Caubel, P., & De Bernardi, B. (2025). Challenges and Innovations in pharmacovigilance and signal management during the COVID-19 Pandemic: An Industry perspective. Vaccines, 13(5), 481. https://doi.org/10.3390/vaccines13050481
[53] Gupta, R., Malhotra, A., &Malhotra, P. (2018). A study on determinants of underreporting of adverse drug reactions among resident doctors. International Journal of Research in Medical Sciences, 6(2), 623.https://doi.org/10.18203/2320-6012.ijrms20180310
[54] Menang, O., Kuemmerle, A., Maigetter, K., &Burri, C. (2023). Strategies and interventionstostrengthenpharmacovigilancesystemsinlow-incomeand middle-income countries: a scoping review. BMJ Open, 13(9), e071079.https://doi.org/10.1136/bmjopen-2022-071079
[55] Balani, A. R., &Grendell, J. H. (2008). Drug-Induced pancreatitis. Drug Safety, 31(10), 823–837. https://doi.org/10.2165/00002018-200831100-00002
[56] Almutairi, M., Almomen, S., Arafah, A. M., Dali, H. A., Hafiz, R. A., &AlOtaibi, A. (2025). Key Findings from Pharmacovigilance Inspections in Saudi Arabia’s Pharmaceutical Sector. Therapeutic Innovation &Regulatory Science, 59(4), 817–824. https://doi.org/10.1007/s43441-025-00781-3
[57] De Jesus, M., Rabbani, G., Ferrer, B., Assaf, A. R., Bader, M., South, B., Leventhal, D.P., Boyles, P., Watt, S. J., &Habtezion, A. (2025). Empowering patients through pharmacovigilance, transparency, and health literacy: a narrative review. Current Medical Research and Opinion, 41(7), 1249–1259. https://doi.org/10.1080/03007995.2025.2534468
[58] Skalli, S. (2023). The Moroccan experience of implementing a university curriculum for thepharmacovigilanceofherbalmedicines(Phytovigilance).DrugSafety,47(3),285–286.https://doi.org/10.1007/s40264-023-01372-7
[59] Corbel-Ecalard, C., Kilgour-Christie, J., Trun, W., & Lewis, D. J. (2023). Negotiating your way through the vigilance agreement maze—is there a better way? Therapeutic Innovation&RegulatoryScience,57(5),1017–1029.https://doi.org/10.1007/s43441-023-00513-5
[60] Inácio, P., Cavaco, A., &Airaksinen, M. (2016). The value of patient reporting to the pharmacovigilance system: a systematic review. British Journal of ClinicalPharmacology, 83(2), 227–246. https://doi.org/10.1111/bcp.13098
[61] Hammad,T.A.,Sabrdaran,S., Aboshady,H.,Rogers,R.,Heim, J.,Bullano,K.,&Ishida, T. (2025). Reflections, operational lessons, and practical insights from a pharmacovigilance inspection: a case example of organizational strategies for medical safety readiness. Therapeutic Advances in Drug Safety, 16, 20420986251363378.https://doi.org/10.1177/20420986251363378
[62] Kant, A. C. (2023). Appeal for increasing the impact of pharmacovigilance. Drug Safety, 47(2), 113–116. https://doi.org/10.1007/s40264-023-01375-4
[63] Wang, F., Hendryx, M., Liu, N., Bidulescu, A., Mitra, A. K., &Luo, J. (2023). SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes. Drug Safety, 47(2), 125–133. https://doi.org/10.1007/s40264-023-01373-6
[64] Lindquist, M. (2008). VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal, 42(5), 409–419. https://doi.org/10.1177/009286150804200501.CIOMS Working Group. Guiding principles for multinational pharmacovigilance collaboration. TherInnovRegul Sci. 2024;58(4):652-61.
[65] International Council for Harmonisation. ICH E2E Pharmacovigilance Planning. ICH; 2004.
[66] Budin-Ljøsne,I.,Teare,H.J.A.,Kaye,J.,Beck,S.,Bentzen,H.B.,Caenazzo,L.,Collett, C., D’Abramo, F., Felzmann, H., Finlay, T., Javaid, M. K., Jones, E., Kati?, V., Simpson, A., &Mascalzoni, D. (2017). Dynamic Consent: a potential solution to some of the challenges of modern biomedical research. BMC Medical Ethics, 18(1), 4.https://doi.org/10.1186/s12910-016-0162-9
[67] Zaguir, N. A., De Magalhães, G. H., & De MesquitaSpinola, M. (2024). Challenges and Enablers for GDPR Compliance: Systematic literature review and future research directions. IEEE Access, 12, 81608–81630. https://doi.org/10.1109/access.2024.3406724
[68] Garashi, H. Y., Steinke, D. T., &Schafheutle, E. I. (2022). A systematic review of pharmacovigilance systems in developing countries using the WHO Pharmacovigilance indicators. Therapeutic Innovation & Regulatory Science, 56(5), 717–743. https://doi.org/10.1007/s43441-022-00415-y
[69] Youngster, I., Arcavi, L., Schechmaster, R., Akayzen, Y., Popliski, H., Shimonov, J., Beig, S., &Berkovitch, M. (2010).Medications and Glucose-6-Phosphatedehydrogenase deficiency.DrugSafety,33(9),713–726.https://doi.org/10.2165/11536520-000000000-00000
[70] Rathod DM, Srivastava S, Deshpande A. Regulatory actions and compliance failures in pharmacovigilance: review of warning letters issued by global agencies. Expert Opin Drug Saf. 2022;21(4):487-96. doi:10.1080/14740338.2022.2039476
[71] Lihite, R. J., &Lahkar, M. (2015). An update on the Pharmacovigilance Programme of India. Frontiers in Pharmacology, 6, 194. https://doi.org/10.3389/fphar.2015.00194
[72]Fornasier, G., Francescon, S., Leone, R., &Baldo, P. (2018). An historical overview over Pharmacovigilance. International Journal of Clinical Pharmacy, 40(4), 744–747. https://doi.org/10.1007/s11096-018-0657-1
[73] Bombardier,C.,Laine,L.,Reicin,A.,Shapiro,D.,Burgos-Vargas,R.,Davis,B.,Day,R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., &Schnitzer, T. J. (2000). Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal of Medicine, 343(21), 1520–1528. https://doi.org/10.1056/nejm200011233432103
[74] Oster,M.E.,Shay,D.K.,Su,J.R.,Gee,J.,Creech,C.B.,Broder,K.R.,Edwards,K.,Soslow, J. H., Dendy, J. M., Schlaudecker, E., Lang, S. M., Barnett, E. D., Ruberg, F. L., Smith,M.J.,Campbell,M.J.,Lopes,R.D.,Sperling,L.S.,Baumblatt,J.A.,Thompson,D.L.,...Shimabukuro,T.T.(2022).MyocarditiscasesreportedaftermRNA-Based COVID-19vaccinationintheUSfromDecember2020toAugust2021.JAMA,327(4),331.https://doi.org/10.1001/jama.2021.24110
[75] Gargano,J.W.,Wallace,M.,Hadler,S.C.,Langley,G.,Su,J.R.,Oster,M.E.,Broder,K.R., Gee, J., Weintraub, E.,Shimabukuro, T., Scobie,H.M., Moulia,D., Markowitz, L. E., Wharton, M., McNally, V. V., Romero, J. R., Talbot, H. K., Lee, G. M., Daley, M. F., & Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morbidity and Mortality Weekly Report, 70(27), 977–982. https://doi.org/10.15585/mmwr.mm7027e2
[76] Rose,J.,Hulscher,N.,&McCullough,P.A.(2024).DeterminantsofCOVID-19vaccine- induced myocarditis. Therapeutic Advances in Drug Safety, 15, 20420986241226566. https://doi.org/10.1177/20420986241226566
[77] Dangy-Caye, A., Mousset, A., Kermad, A., Bouché-Bazerolle, L., Bujar, M., De Lucia, M., McAuslane, N., &Lumsden, R. (2025). Harmonizing health: a global analysis of pharmaceutical regulatoryactivitiesbyinternational regulatoryorganizations. Frontiersin Medicine, 12, 1636269. https://doi.org/10.3389/fmed.2025.1636269
[78] Teixeira, T., Kweder, S. L., & Saint?Raymond, A. (2019). Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talkingto Each Other? Clinical Pharmacology & Therapeutics, 107(3), 507–513. https://doi.org/10.1002/cpt.1617
[79] Alexe, A., Eisele, O., Fernandes, M. F. S., Garg, A., Kovacs, B., Wurst, K., Balramsingh? Harry, L., Abramova, N., Zheteyeva, Y., & Lewis, D. (2023). Call to action: Harmonizationofpharmacovigilanceregulationsforpost?marketingpregnancyand breastfeeding safety studies. British Journal of Clinical Pharmacology, 90(3), 715–721. https://doi.org/10.1111/bcp.15920
[80] Fusaroli, M., Salvo, F., Begaud, B., AlShammari, T. M., Bate, A., Battini, V., Brueckner, A., Candore, G., Carnovale, C., Crisafulli, S., Cutroneo, P. M., Dolladille, C., Drici, M., Faillie, J., Goldman, A., Hauben, M., Herdeiro, M. T., Mahaux, O., Manlik, K., . . . Khouri, C. (2024). The REporting of a Disproportionality Analysis for DRUG Safety Signal Detection using Individual Case SafetyReports in PharmacoVigilance (READUS- PV): Explanation and Elaboration. Drug Safety, 47(6), 585–599. https://doi.org/10.1007/s40264-024-01423-7
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications